The two sessions will be held in 2022,
A number of people's congress deputies and CPPCC members from the medical and health circles
Contribute ideas around the development of medicine.
Come and see if there's anything you care about.
1 Wang Ningli: It is recommended that the basic drug list include more ophthalmic drugs that are clinically in line with the clinic
Wang Ningli, member of the National Committee of the Chinese People's Political Consultative Conference and head of the National Anti-Blindness Technical Guidance Group, suggested in his proposal that the ophthalmic drugs in the National Essential Drugs Catalogue (2018 Edition) be adjusted to include drugs that are more suitable for the changing needs of Chinese ophthalmic diseases, have better efficacy and higher clinical value, especially the clinical first-line treatment drugs for irreversible blinding eye diseases for children, workers and the elderly, and increase the accessibility of clinical ophthalmic drugs covering the whole life cycle of eye health in national drugs.
Professor Wang Ningli
Wang Ningli suggested that the relevant departments should proceed from the focus of policy attention, consider from the perspective of patient and social benefits, conform to the changes in clinical needs, scientifically adjust the catalog, include more drugs that meet the needs of clinical treatment and have high clinical value, and appropriately transfer out the old ophthalmic drugs that have been discontinued and have fewer clinical uses and large side effects in the catalog, so as to further enhance the accessibility of clinical first-line drugs for key populations and national key ophthalmic diseases.
2 Zhang Zheren: The management of drugs in excess of the instructions urgently needs to be established
Zhang Zheren, member of the National Committee of the Chinese People's Political Consultative Conference and former vice chairman of the Shanghai Municipal Committee of the Peasants' and Workers' Party, suggested that the National Health Commission, the State Food and Drug Administration, the State Medical Insurance Bureau and other departments should organize domestic medical, pharmaceutical, and management experts to study and promulgate the "Measures or Guiding Principles for the Administration of Drugs in Excess of Instructions" as soon as possible, standardize the management process of drugs in excess of instructions, and strictly implement them.
He also suggested that the State Food and Drug Administration organize relevant societies and associations to carry out demonstrations of the varieties of super-drug instructions with sufficient evidence-based evidence and commonly used in clinical practice, and urge relevant enterprises to modify the drug instructions in a timely manner for the varieties that have passed the demonstration, so as to reduce the use of some ultra-drug instructions; it is recommended that the State Medical Insurance Bureau organize relevant societies and associations to carry out demonstrations for the varieties of super-drug instructions with sufficient evidence-based evidence and common clinical use, and include the research on the indications for the varieties of super-drug instructions passed by the demonstration into the scope of medical insurance payment. Reduce the financial burden on patients.
3 Ma Yide: Accelerating the Promotion of Mainland Innovative Drugs "Going Global"
Ma Yide, a deputy to the National People's Congress and a professor at the School of Public Administration and the School of Intellectual Property of the University of Chinese Academy of Sciences, proposed to seize the opportunity to accelerate the "going out" of innovative drugs in the mainland.
Professor Ma Yide
Ma Yide said that although the mainland innovative drug industry has reached a certain level, due to the short development history, the international influence has not yet reached a scale, and when "going to sea", it is more subject to the non-technical barriers set by some developed countries relying on rules such as patents and systems. He suggested that the drug regulatory authorities and the co-construction countries should strengthen drug regulatory and certification policies and technical exchanges, gradually realize the sharing and mutual recognition of clinical trial data, inspection standards and results, and accelerate the marketing recognition and clinical use of innovative drugs in the "Belt and Road" countries in the mainland. It is recommended that relevant departments establish a joint working mechanism, study and coordinate to solve new situations and new problems encountered in the "going out" of innovative drugs, further increase support in terms of policy systems, resource allocation, talent training, etc., and establish a sound ecological system for innovative drugs "going out".
4 Xu Ziqiang: It is recommended that emergency drugs be included in the scope of medical insurance reimbursement
Xu Ziqiang, member of the National Committee of the Chinese People's Political Consultative Conference and director of the emergency department of the First People's Hospital of Chenzhou City, Hunan Province, suggested that emergency drugs should be included in the scope of medical insurance reimbursement. Emergency drugs are mostly used in emergency departments and intensive care units, according to the existing medical insurance policy stipulates that emergency department drugs are often not reimbursed, and the high price of "life-saving" drugs invisibly increases the burden on patients, especially patients with economic difficulties.
Professor Xu Ziqiang
5 Niu Chaoshi: Increase investment in original research drugs and solve the problem of expensive drugs
Niu Chaoshi, deputy to the National People's Congress and director of the Department of Neurosurgery at the First Affiliated Hospital of the University of Science and Technology of China, believes that to solve the problems of expensive drugs and insufficient supply of drugs, it is necessary to increase the research and development of original research drugs, seize the opportunity for the research and development of biological drugs, deepen the research and development of chronic disease drugs, and increase the basic research of traditional Chinese medicine.
In addition, it is also necessary to improve the ability to use drugs at the grass-roots level. Many grassroots doctors lack clinical experience, and they prescribe drugs to patients according to the experience and instructions of the older generation, and they cannot use the right drugs and use good drugs in a targeted manner, resulting in poor treatment effects for patients.
6 Yang Jiefu: Improve the innovation of domestic high-end medical devices
Yang Jiefu, member of the National Committee of the Chinese People's Political Consultative Conference and director of the Department of Cardiology of Beijing Hospital, proposed that the state should provide special support and investment for core high-end equipment, such as MRI, pacemaker and other card neck technologies.
Professor Yang Jiefu
He also suggested that we should adhere to the form of combining production, education and research, form a full-chain innovation model of "technology research and development, product development, application demonstration, and market promotion", and strengthen the cross-integration of multiple disciplines. Improve the incentive mechanism conducive to innovative products, establish a risk protection mechanism, and enhance the enthusiasm of enterprises in research and development and production. Introduce and cultivate first-class talents, encourage them to boldly carry out original research and application, and build an innovative team around its core system. Encourage the use of domestic equipment, in addition to giving "green channels" in the approval process and product bidding, the state should introduce corresponding policies to gradually increase the proportion of government procurement of domestic innovative products.
7 Season Jiafu: Building an Open Innovation Ecosystem for Pharmaceuticals
Ji Jiafu, member of the National Committee of the Chinese People's Political Consultative Conference and president of Peking University Cancer Hospital, brought suggestions on the construction of a pharmaceutical innovation ecology, and called for increasing investment in science and technology to promote the transformation and penetration of scientific and technological achievements.
Professor Tygarfu
Ji Jiafu believes that the strategic role of pharmaceutical innovation in social and economic development is becoming more and more significant, and the mainland should base itself on the goal of leading the global pharmaceutical innovation network, focusing on further winning the European and American markets and widely recognized by the Belt and Road countries to carry out top-level design. Improve the original high-clinical value product research and development and overseas strategy, and promote the transformation of domestic pharmaceutical companies from local leaders to global innovation drivers. Regulators should continue to actively participate in the Drug Inspection Agreement and the Drug Inspection Cooperation Program, and gradually increase the international acceptance of local pharmaceutical products. Explore new ideas for drug discovery, dig deep into the value of local original innovative drugs, build a competitive advantage of differentiated innovation, and enhance the recognition of the mainland pharmaceutical industry in the global drug supply map.
In addition, in terms of improving the talent training system, a high-level innovation team is an important guarantee, and it is urgent to strengthen the training and industry attention. Under the leadership of high-quality and high-innovation teams, we will deeply explore and explore unmet clinical needs, better promote the integration of government, industry, education and research cooperation, and improve the penetration speed and success rate of the transformation of scientific and technological achievements.
8 Li Weimin: Build a "trinity" chronic disease collaborative prevention and control system
Li Weimin, deputy to the National People's Congress and president of West China Hospital, focused his attention on the prevention and control of chronic diseases this year, and proposed to build a "trinity" chronic disease collaborative prevention and control system, that is, to build a trinity of chronic disease collaborative prevention and control system through medical insurance and commercial insurance collaboration, hospital-to-hospital collaboration, and online and offline collaboration.
Professor Li Weimin
On the basis of improving basic medical security as the main body, we will support the healthy development of various forms of supplementary insurance such as commercial insurance, provide solid protection for the prevention and control of chronic diseases, and reduce the economic burden on patients. Give full play to the role of medical and health institutions at different levels, supported by information technology, establish a specialized medical association with clear responsibilities and close collaboration, take the patient as the center, and realize the whole process of chronic disease prevention, diagnosis, treatment and health management. Combining online and offline, patients clarify the diagnosis and treatment plan in the hospital, and then use The Internet medical treatment for follow-up management, including medication guidance, follow-up monitoring, family rehabilitation, etc., to build a whole-chain health protection system.
Reprint 丨 People's Daily health client